ArticleOpen forum infectious diseases2022
A Novel Program to Provide Drug Recovery Assistance and Outpatient Parenteral Antibiotic Therapy in People Who Inject Drugs.
Article in Open forum infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 8 citations in OpenAlex.
- 2026 Updated good practice recommendations for outpatient parenteral antimicrobial therapy (OPAT) in adults and children in the UK.JAC-antimicrobial resistance · 2026Review
- Factors associated with mortality following hospitalization among veterans with opioid use disorder.Journal of substance use and addiction treatment · 2025Article
- Impact of Substance Use Disorders on Outcomes of Medically Insured Persons Receiving Multiweek Outpatient Parenteral Antimicrobial Therapy: a Claims-based Cohort Study From 2015 to 2020.Open forum infectious diseases · 2025Article
- Use of Dalbavancin in Treatment of Acute Bacterial Skin and Skin Structure Infections: Case Series from a Canadian Perspective.Journal of the Association of Medical Microbiology and Infectious Disease Canada = Journal officiel de l'Association pour la microbiologie medicale et l'infectiologie Canada · 2025Article
- Clinical outcome and cost of intravenous, OPAT, and oral treatment of Gram-negative bacteremia.Qatar medical journal · 2025Article
- Management of People Who Inject Drugs With Serious Injection-Related Infections in an Outpatient Setting: A Scoping Review.Open forum infectious diseases · 2024Article
- Partial-Oral Antibiotic Therapy for Bone and Joint Infections in People With Recent Injection Drug Use.Open forum infectious diseases · 2023Article
- A Baker's Dozen of Top Antimicrobial Stewardship Intervention Publications in Non-Hospital Care Settings in 2021.Open forum infectious diseases · 2022Review
- Medication for opioid use disorder at hospital discharge is not associated with intravenous antibiotic completion in post-acute care facilities.Therapeutic advances in infectious diseaseArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSafe hospital discharge on parenteral antibiotic therapy is challenging for people who inject drugs (PWID) admitted with serious bacterial infections (SBI). We describe a Comprehensive Care of Drug Addiction and Infection (CCDAI) program involving a partnership between Intermountain Healthcare hospitals and a detoxification facility (DF) to provide simultaneous drug recovery assistance and parenteral antibiotic therapy (DRA-OPAT).
methodsThe CCDAI program was evaluated using a pre-/poststudy design. We compared outcomes in PWID hospitalized with SBI during a 1-year postimplementation period (2018) with similar patients from a historical control period (2017), identified by propensity modeling and manual review.
resultsEighty-seven patients were candidates for the CCDAI program in the implementation period. Thirty-five participants (40.2%) enrolled in DRA-OPAT and discharged to the DF; 16 (45.7%) completed the full outpatient parenteral antibiotic therapy (OPAT) duration. Fifty-one patients with similar characteristics were identified as a preimplementation control group. Median length of stay (LOS) was reduced from 22.9 days (interquartile interval [IQI], 9.8-42.7) to 10.6 days (IQI, 6-17.4) after program implementation (
conclusionsPartnerships between hospitals and community resources hold promise for providing resource-efficient OPAT and drug recovery assistance. We observed significant reductions in LOS and cost without increases in readmission rates; 1-year mortality may have been improved. Further study is needed to optimize benefits of the program.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.